Literature DB >> 11870269

Sidebranch compromise during percutaneous coronary interventions.

Neeraj Prasad1, Peter H Seidelin.   

Abstract

Justified concerns exist about coronary balloon angioplasty and stent deployment when a sidebranch is within the vicinity of the interventional site. Assessment of the jeopardized sidebranch for the risk of compromise can be made by evaluating the sidebranch diameter, the myocardial territory supplied, the relationship to the parent vessel lesion and the presence of ostial disease. This can help in the decision-making process of the proposed intervention, allowing a strategy to be pre-planned in the event of sidebranch compromise. Sidebranch compromise associated with flow reduction in a branch vessel that is of medium or large diameter and serving moderate or large territory is often associated with a cardiac enzyme rise. It is now recognized that any cardiac enzyme rise after intervention is associated with increased long-term risk and such compromised sidebranches may be considered for re-opening to help preserve the myocardium. A variety of balloon angioplasty and stenting techniques are described for sidebranch compromise with some short-term success. Long-term outcomes and effect of sidebranch intervention have not yet been fully evaluated.

Entities:  

Mesh:

Year:  2002        PMID: 11870269

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  2 in total

1.  Kissing Balloon Technique for Angioplasty of Tibioperoneal Arteries Bifurcation Using Pedal Arterial Retrograde Revascularization.

Authors:  Ahmed Amro; Obadah Aqtash; Adee Elhamdani; Mehiar El-Hamdani
Journal:  Case Rep Vasc Med       Date:  2018-12-25

2.  A Novel Tram Stent Method in the Treatment of Coronary Bifurcation Lesions - Finite Element Study.

Authors:  Mark C Arokiaraj; Gianluca De Santis; Matthieu De Beule; Igor F Palacios
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.